Skip to main content

NCI-H358 Transfection Reagent (Bronchioalveolar Cells)

The NCI-H358 cell line was first established in 1981 from removed bronchiole tissue of a patient suffering from bronchioalveolar carcinoma (lung cancer). The tissue was removed from the patient prior to any administered chemotherapy treatments. The NCI-H358 cell line has a doubling time of about 38 hours, it has detectable Clara cells and is an exceptional transfection host. This cell line is also a great candidate for in vitro research studies, such as those at Altogen Biosystems.The in vitro research models are helpful to solving lung cancer and useful as transfection hosts. 

 Transfection Reagent for NCI-H358 Cells (Bronchioalveolar Cells, CRL-5807)
Labels:

Popular posts from this blog

Altogen Biosystem’s Lung Cancer Xenografts

Altogen Biosystems is a global producer and custom research organization for the pharmaceutical industry. Biological products and other goods include ELISA testing, optimization of preclinical research, stable transfection of cells, IND applications and more. Dedicated to helping researchers with state-of-the-art and efficient services, Altogen Biosystems strives to further modern clinical techniques. Visit the Altogen Biosystems website for lung xenograft models and related tools for preclinical drug testing.
Post a Comment
Read more

NCI-H358 Cell Line

NCI-H358 is a tumorigenic cell line that was established in 1981 from the bronchiole tissue of a male with bronchioalveolar carcinoma. NCI-H358 cells display adherent cultural properties in vitro  and an epithelial morphology. NCI-H358 produces lung surfactant associated protein A (SP-A) and expresses the RNA of SP-A. NCI-H358 cells are suitable transfection hosts, and Altogen Biosystems offers a NCI-H358 transfection reagent to transfect NCI-H358 cells. The NCI-H358 cell line can be used to study lung cancer and develop therapeutics.
Post a Comment
Read more